Sorrento Announces That It Has Acquired A Majority Ownership In Diagnostic Manufacturer Zhengzhou Fortune Bioscience In Response To Increasing Worldwide Demand For Covistix™
Acquiring Company
Sorrento Therapeutics
Acquired Company
Majority Ownership
San DiegoBiotechnologyHealth CareScience And EngineeringDescription
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the acquisition of a majority ownership of Zhengzhou Fortune Bioscience Co., Ltd. (“FortuneBio”). This acquisition is in response to dramatically increasing demands worldwide and planned product build-up in anticipation of potential additional approvals for Sorrento’s COVISTIXTM COVID-19 VIRUS Rapid Antigen Detection Test.
Quick answer
Sorrento Therapeutics is acquiring Majority Ownership, announced February 17, 2022. Sorrento Therapeutics is based in San Diego, California, United States.
- How much did Sorrento Therapeutics pay for Majority Ownership?
- The deal value was not disclosed.
- What does Sorrento Therapeutics do?
- Sorrento Therapeutics, Inc. is a clinical stage and commercial biopharmaceutical company focused on delivering innovative and clinically meaningful therapies to address unmet medical needs.
- Where are Sorrento Therapeutics and Majority Ownership based?
- Sorrento Therapeutics is based in San Diego, California, United States.
- Who are the decision-makers at Sorrento Therapeutics?
- Fundz holds 1 contact at Sorrento Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Science And Engineering and Biotechnology
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Intellia Therapeutics Announces Acquisition Of Rewrite Therapeutics (February 3, 2022)
- Element Biosciences Closes Acquisition Of Loop Genomics (February 8, 2022)
- Emmes Acquires Casimir, Its Fourth Major Acquisition (March 10, 2022)
- Medtronic To Acquire Affera (January 10, 2022)
- Lumanity Acquires Innovative Edge (March 30, 2022)
- Incannex To Acquire Apirx Pharmaceuticals Usa, Llc (March 24, 2022)
Who to call at Sorrento Therapeutics, and when
When Sorrento Therapeutics changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Sorrento Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Sorrento Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Sorrento Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Sorrento Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Majority Ownership?
Majority Ownership was acquired by Sorrento Therapeutics, based in San Diego. The deal was reported on February 17, 2022. Sorrento Therapeutics, Inc. is a clinical stage and commercial biopharmaceutical company focused on delivering innovative and clinically meaningful therapies to address unmet medical needs. Sorrento Therapeutics is privately held and operates in Biotechnology.
When did Sorrento Therapeutics acquire Majority Ownership?
Sorrento Therapeutics's acquisition of Majority Ownership was reported on February 17, 2022. Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the acquisition of a majority ownership of Zhengzhou Fortune Bioscience Co., Ltd. (“FortuneBio”). Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Majority Ownership do?
Majority Ownership is the company acquired in this transaction. It is privately held.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.